DISCOVER FINANCE

For generations, the path for young bankers entering Wall Street was, for the most part, similar. Late nights with heads buried in PowerPoint decks, analyzing numbers and spreadsheets that made heads spin, creating financial statements that stretched pages. But what OpenAI just created may mean humans no longer need to do this work. On September 10, 2026, OpenAI launched ChatGPT for Financial Services. In coordination with Morgan Stanley and Evercore, the system serves as a

After years of hesitation, Wall Street is pouring money back into biotechnology. On September 18, 2026, Electra Therapeutics went public, raising $350 million in one of the year’s largest biotech IPOs. Selling 23.3 million shares at $15 each, the company reached a market value of roughly $1 billion. This decision, however, is part of a much larger comeback. Electra is the 21st biotech company to go public this year. 11 of these companies have managed to individually raise ov

OpenAI has spent years racing to build the most powerful artificial intelligence. That race is now causing the company to put one of the most anticipated IPOs in history on hold. Earlier this year, OpenAI was preparing for an IPO that valued the company at around $1 trillion. Despite potentially being one of the largest listings ever, CEO Sam Altman has decided not to go public in 2026, arguing that current concerns over AI safety make this the wrong time to enter the public

Nvidia has led the AI chip boom. Its dominance doesn’t seem to be stopping anytime soon. On September 3, 2026, Nvidia announced that it would acquire Hugging Face for $12.93 billion, making this acquisition the second-largest in the company’s history. Despite only just reaching its tenth anniversary, Hugging Face has become one of the world’s biggest platforms for AI developers. Referred to as the “GitHub of AI”, the platform serves as the default place where AI projects sta

In early August, a deadline approached for the United States to impose new 50% Section 338 tariffs on $ 20 billion worth of Canadian exports. Both countries met for trade negotiations, and it seemed as if a deal was going to occur, with Canadian negotiators frequently traveling to Washington before the August 19th deadline. And the day before the deadline, Trump announced he would postpone tariffs while alluding to the idea that the countries had come to a deal. Both countrie

Novartis may have just lost a drug that analysts thought could generate up to $6 billion a year. On September 4, 2026, Novartis announced that pelacarsen, its experimental cardiovascular drug, failed a major phase 3 trial. The drug was intended to lower lipoprotein(a), a genetically determined risk factor for heart disease that affects roughly one in five people worldwide. This wasn’t just an opportunity for medicine. From a financial perspective, the commercial stakes were